Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 17Terminated 7Not yet recruiting 6Active not recruiting 4Unknown 3Recruiting 3Withdrawn 1

Sponsor Class

INDUSTRY 9OTHER 4NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Thoracic 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Recurrence 1Gallbladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 184Nivolumab 180Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 111Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74Radiation 73atezolizumab 72venetoclax 68fludarabine 68Gemcitabine 68Standard of Care 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × AZD 6244 × Clear all
NCT03392246 2026-05-27

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
25 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03162627 2026-04-15

Selumetinib and Olaparib in Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
90 enrolled
Breast

Breast Neoplasms

NCT02151084 2025-12-16

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
57 enrolled
Gastrointestinal

Gallbladder Neoplasms, Recurrence

NCT02299999 2025-01-15

SAFIR02_Breast

UNICANCER

Phase 2 Active not recruiting
1,460 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡